New results presented at Cardiovascular Research Technologies (CRT) 2023 demonstrate the safety of Navitor™ TAVI system and its effectiveness in minimizing blood leakage around the valve implant Latest data continue to show the benefits of Amplatzer™ Amulet™ LAA Occluder’s immediate […]
Tag: Abbott
ABBOTT TO ACQUIRE CARDIOVASCULAR SYSTEMS, INC.
Abbott will gain an innovative, complementary solution in treating vascular disease through CSI’s leading atherectomy system, which prepares vessels for angioplasty or stenting to restore blood flow CSI’s offering will support Abbott’s ability to provide better care for patients with […]
Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook
Fourth-quarter sales of $10.1 billion; full-year 2022 sales of $43.7 billion Full-year 2022 sales growth of 1.3 percent; organic sales growth of 6.4 percent Full-year 2022 GAAP diluted EPS of $3.91; adjusted diluted EPS of $5.34 Continues to strengthen portfolio with steady cadence of […]
Abbott Receives FDA Approval for Navitor™, a Next-Generation TAVI System Designed to Treat Aortic Stenosis
Abbott’s new Navitor device features advancements to improve patient care, including reducing or eliminating risk of blood leakage around valve implant Transcatheter aortic valve implantation (TAVI) offers minimally invasive alternative to surgery for people with aortic stenosis, a common and […]
Investor Insights: Sabir Rassiwalla – What Can We Expect From CRG in the Future? (Part 3)
McDermott + Bull Partner Ken Dropiewski talks with CRG Director Sabir Rassiwalla about what drove him to CRG after a long tenure with Abbott.
Late-Breaking Data Show Breadth of Abbott’s Minimally Invasive Structural Heart Technologies
Five late-breaking presentations at TCT 2022 highlight the impact of Abbott’s structural heart devices to repair or replace heart valves and close openings in the heart New data reinforce the safety and effectiveness of MitraClip™ for treating mitral regurgitation Results […]
Investor Insights: Sabir Rassiwalla – What Makes CRG Different From Other Healthcare Investors? (Part 2)
McDermott + Bull Partner Ken Dropiewski talks with CRG Director Sabir Rassiwalla about how CRG is different from healthcare investment partners in the market.
THREE-YEAR DATA ON WORLD’S SMALLEST HEART DEVICE SHOW BENEFITS OF FIXING HOLES IN NEWBORN HEARTS WITHOUT SURGERY
Results reinforce that Amplatzer Piccolo™ Occluder is safe and effective for closing an opening in the heart known as a “patent ductus arteriosus” (PDA) in newborns Study found low adverse event rates following a Piccolo procedure, showing additional benefit of […]
ABBOTT ANNOUNCES EUROPEAN LAUNCH OF AMPLATZER™ TALISMAN™ SYSTEM TO CLOSE HOLE IN HEART FOR PEOPLE AT RISK OF RECURRENT STROKE
– Abbott’s Talisman system seals an opening in the heart known as a “patent foramen ovale” (PFO) to prevent blood clots from passing from the right to the left side of the heart and on to the brain, where they […]
New Data Show Abbott’s HeartMate 3™ Heart Pump Extends Life Beyond Five Years for Advanced Heart Failure Patients
New data from the MOMENTUM 3 study showed for the first time that a heart pump can extend survival to five years and beyond for advanced heart failure patients Prior data1 have shown survival for advanced heart failure patients who […]